Cargando…
Immune-related adverse events caused by treatment with pembrolizumab in a patient with lung cancer who infected influenza virus
A 67-year-old man with stage IV B lung adenocarcinoma was treated with pembrolizumab. The patient was admitted to the hospital because of influenza on the day of the second cycle of pembrolizumab treatment. He was diagnosed with pneumonia and was treated with antiviral drugs and steroids. However, t...
Autores principales: | Takemura, Masao, Motegi, Mitsuru, Kuroiwa, Yuya, Itai, Miki, Taguchi, Kohei, Umetsu, Kazue, Uchida, Megumi, Kounoc, Shunichi, Sato, Mari, Masubuchi, Hiroaki, Yamaguchi, Aya, Yamaguchi, Koichi, Ikeda, Kana, Nakagawa, Junichi, Maeno, Toshitaka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892985/ https://www.ncbi.nlm.nih.gov/pubmed/33643837 http://dx.doi.org/10.1016/j.rmcr.2021.101361 |
Ejemplares similares
-
A case of Trousseau syndrome caused by pulmonary adenocarcinoma that was controlled for one year and 10 months with thrombosis treatment using an EGFR tyrosine kinase inhibitor and chemotherapy
por: Masubuchi, Hiroaki, et al.
Publicado: (2015) -
Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
por: Yamaguchi, Ou, et al.
Publicado: (2023) -
Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
por: Takehara, Kazutaka, et al.
Publicado: (2022) -
WHO, RECIST, and immune-related response criteria: is it time to revisit pembrolizumab results?
por: Ades, Felipe, et al.
Publicado: (2015) -
Sarcoid‐like reaction of the extrathoracic lymph node in a patient with lung adenocarcinoma treated with pembrolizumab
por: Takamori, Shinkichi, et al.
Publicado: (2021)